PubRank

Barbara L Weber

Author PubWeight™ 310.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mutations of the BRAF gene in human cancer. Nature 2002 65.42
2 Patterns of somatic mutation in human cancer genomes. Nature 2007 38.41
3 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012 31.78
4 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 14.62
5 BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002 8.55
6 Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004 8.35
7 microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006 8.24
8 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002 8.09
9 Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005 7.66
10 A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005 6.70
11 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004 5.38
12 Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008 4.79
13 Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007 4.69
14 Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003 4.03
15 miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2007 3.93
16 Breast and ovarian cancer. N Engl J Med 2003 3.84
17 Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006 3.73
18 Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002 3.65
19 Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006 3.42
20 STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 2006 3.21
21 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006 3.02
22 High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005 2.72
23 Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005 2.70
24 A comparison of DNA copy number profiling platforms. Cancer Res 2007 2.63
25 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004 2.51
26 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006 2.49
27 A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 2006 2.35
28 MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008 2.35
29 The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005 2.26
30 Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002 2.25
31 Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 2006 2.23
32 Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003 2.19
33 HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest 2010 2.00
34 A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008 1.99
35 Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007 1.94
36 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 2003 1.90
37 Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 2004 1.84
38 Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005 1.80
39 Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006 1.70
40 Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 2003 1.58
41 Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology 2002 1.58
42 Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys 2004 1.57
43 BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003 1.55
44 SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 2004 1.51
45 Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007 1.48
46 High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005 1.47
47 Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test 2008 1.46
48 ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006 1.41
49 Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008 1.37
50 Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 2005 1.37
51 Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer Res 2007 1.36
52 Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol 2009 1.25
53 Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002 1.23
54 Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011 1.18
55 MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004 1.18
56 CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data. Bioinformatics 2005 1.16
57 Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 2009 1.14
58 Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 2011 1.12
59 A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res 2011 1.10
60 Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test 2004 1.09
61 BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 2002 1.06
62 Genetic variants of uncertain significance: flies in the ointment. J Clin Oncol 2008 1.03
63 CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Hum Mol Genet 2002 1.01
64 Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res 2007 0.95
65 The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2005 0.94
66 Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. Mol Cancer Ther 2008 0.90
67 Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. In Vitro Cell Dev Biol Anim 2006 0.90
68 ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol 2006 0.88
69 A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 2006 0.86
70 Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. Cancer Lett 2005 0.85
71 Clinical management of BRCA1 and BRCA2 mutation carriers. Nat Clin Pract Oncol 2006 0.81
72 Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol 2003 0.81
73 Resolving ATM haplotypes in whites. Am J Hum Genet 2003 0.78
74 Risk management in BRCA1 and BRCA2 mutation carriers: lessons learned, challenges posed. J Clin Oncol 2002 0.77
75 Why not to screen high-risk women anticipating BRCA1/BRCA2 testing for psychological distress. J Consult Clin Psychol 2002 0.75
76 Recent advances in breast cancer biology. Curr Opin Oncol 2002 0.75
77 Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clin Breast Cancer 2007 0.75
78 Identification of a submicroscopic deletion of SHH associated with the holoprosencephaly spectrum by array-based CGH. Clin Genet 2006 0.75